SCHEMBL5714916

SCHEMBL5714916

Cc1cc(CCN2CCN(C(=O)Oc3ccc(CCN4C(=O)CC(C)(C)CC4=O)cn3)CC2)on1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP4F2 P78329 1/20 0.34
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
CYP2C19 P33261 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715437 0.90 MGLL (0.37) SMN1; SMN2HTR2ATHRB
SCHEMBL5714397 0.87 PKM (0.36) SMN1; SMN2CYP4F2PIK3CAMTOR
SCHEMBL5714647 0.83 HTR1A (0.36) HTR1ACYP4F2DRD2HTR2ACYP1A2
SCHEMBL5714952 0.83 HRH3 (0.36) HTR1ACYP4F2DRD2HTR2ACYP1A2
SCHEMBL5715300 0.82 HTR1A (0.40) HTR1ADRD2HTR2ATHRB
SCHEMBL5715203 0.82 KDM4E (0.37) HTR1ASMN1; SMN2DRD2HTR2ACYP1A2
SCHEMBL5714209 0.82 CYP3A4 (0.40) HTR1ASMN1; SMN2CYP4F2DRD2HTR2A
SCHEMBL5715294 0.81 HTR1A (0.38) HTR1ACYP4F2DRD2HTR2ATHRB
SCHEMBL5715533 0.81 HTR1A (0.35) HTR1ACYP4F2DRD2HTR2ATHRB
SCHEMBL5714101 0.81 HTR1A (0.35) HTR1ACYP4F2DRD2HTR2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL HTR1A 2790/4885SMN1; SMN2 3125/4885CYP4F2 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.